$20.60
1.81% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US07373V1052
Symbol
BEAM

Beam Therapeutics Inc Stock price

$20.60
-10.02 32.72% 1M
+2.85 16.06% 6M
-4.20 16.94% YTD
-3.89 15.88% 1Y
-24.81 54.64% 3Y
-21.03 50.52% 5Y
+1.85 9.87% 10Y
+1.85 9.87% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.38 1.81%
ISIN
US07373V1052
Symbol
BEAM
Industry

New AI Insights on Beam Therapeutics Inc Insights AI Insights on Beam Therapeutics Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.1b
Net debt
positive
Cash
$1.1b
Shares outstanding
101.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.2 | 49.8
EV/Sales
18.9 | 24.7
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
66.5%
Return on Equity
-51.4%
ROCE
-41.3%
ROIC
-429.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$55.7m | $42.7m
EBITDA
$-444.2m | $-465.2m
EBIT
$-466.3m | $-487.6m
Net Income
$-414.6m | $-448.4m
Free Cash Flow
$-352.4m
Growth (TTM | estimate)
Revenue
-84.1% | -32.7%
EBITDA
-176.1% | -18.2%
EBIT
-155.3% | -17.3%
Net Income
-188.8% | -19.0%
Free Cash Flow
-142.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-797.5% | -1,088.3%
EBIT
-837.1%
Net
-744.4% | -1,048.9%
Free Cash Flow
-632.6%
More
EPS
$-4.0
FCF per Share
$-3.5
Short interest
22.0%
Employees
483
Rev per Employee
$130.0k
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Beam Therapeutics Inc forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
56 56
84% 84%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 110 110
13% 13%
198%
- Research and Development Expense 412 412
1% 1%
739%
-444 -444
176% 176%
-798%
- Depreciation and Amortization 22 22
1% 1%
40%
EBIT (Operating Income) EBIT -466 -466
155% 155%
-837%
Net Profit -415 -415
189% 189%
-744%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025, at 3:30 p.m.
Neutral
GlobeNewsWire
16 days ago
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting First Subject Dosed with BEAM-103, ...
Neutral
GlobeNewsWire
17 days ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the 67th American Society of Hematology (ASH) Annual Meet...
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 483
Founded 2017
Website beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today